All In Biotech

Drug Trial Radar · NCT07683325

NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients With Fibrostenosing Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 31, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
Agomab Spain S.L.U.Industry
Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the efficacy, safety, and dose-response relationship of ontunisertib in participants with CD and symptomatic strictures, and contribute to the validation of novel endpoints to assess potential treatment benefit in patients with fibrostenosing Crohn's disease (FSCD). The participants will be in the trial for a duration of up to 60 weeks, consisting of a 6-week screening period (with 2 screening visits), a 52-week treatment period, and a 2-week follow-up period. The visit frequency in the treatment period will be every 6 to 8 weeks.

Conditions

  • Fibrostenotic Crohn's Disease

Interventions

  • OntunisertibDrug

    Oral capsule

  • OntunisertibDrug

    Oral capsule

  • OntunisertibDrug

    Oral capsule

  • PlaceboDrug

    Matching oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving endoscopic passability of the ileal index strictureTime frame: At week 24

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • GI Alliance

    Sun City, Arizona · Recruiting

  • Synergy Healthcare, LLC

    Bradenton, Florida · Recruiting

  • Albany Gastroenterology Consultants

    Albany, New York · Recruiting

  • University Gastroenterology

    Providence, Rhode Island · Recruiting

  • GI Alliance

    Cedar Park, Texas · Recruiting

  • GI Alliance - Fort Worth

    Fort Worth, Texas · Recruiting

  • Amel Med LLC

    Georgetown, Texas · Recruiting

  • Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje"

    Belgrade, Serbia · Recruiting

  • Clinical Hospital Center Bezanijska Kosa

    Belgrade, Serbia · Recruiting

  • Clinical Hospital Center Zvezdara (CHCZ)

    Belgrade, Serbia · Recruiting

  • Royal London Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.